GE HealthCare Secures FDA Clearance for SIGNA MRI Trio with 65% Lower Power Demand
GE HealthCare won FDA 510(k) clearances for its SIGNA Sprint with Freelium, SIGNA Bolt 3T and AI-powered SIGNA One, offering up to 65% lower peak power demand and 34% reduced equipment room space. Shares trade 5% above their 20-day average and carry a Buy rating with a $93.35 price target.
1. FDA 510(k) Clearances for SIGNA MRI Portfolio
GE HealthCare obtained FDA 510(k) clearances for three next-generation MRI products. SIGNA Sprint with Freelium enables near helium-free operation, SIGNA Bolt 3T delivers advanced high-field imaging and SIGNA One integrates an AI-driven workflow ecosystem.
2. Sustainability and Performance Improvements
The new MRI systems promise up to 65% reduction in peak power demand and 34% less equipment room footprint. SIGNA Sprint slashes helium reliance below 1%, while AI tools in SIGNA One enhance exam planning, automated patient positioning and post-scan processing.
3. Stock Reaction and Technical Momentum
Following the FDA announcement, shares rose over 1% intraday and now trade about 5% above their 20-day moving average and 6.6% above their 100-day average. Neutral RSI and a positive MACD crossover suggest modest bullish sentiment.
4. Analyst Consensus and Price Targets
Analysts maintain a Buy consensus on GE HealthCare with an average target of $93.35. Recent actions include Stifel raising its target to $98 and BTIG upholding a Buy rating at $91, underscoring confidence in the company’s innovation roadmap.